Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 81 - 90 of 133

Selected Filters:
6 April 2023

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

This journal article from Antimicrobial Agents and Chemo Therapy shares an extended report on HIV infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm).

Monitoring & Evaluation

External Link
17 March 2023

Guidance: Standard Operating Procedures for Addressing Partner Relationships and Gender-Based Violence in Pre-Exposure Prophylaxis (PrEP) Services

Standard Operating Procedure Guidance Evidence has shown that intimate partner violence (IPV) may act as a barrier to accessing HIV services, including PrEP services. IPV is associated with lower PrEP uptake and adherence and increased PrEP interruption among cisgender women. Although cisgender women have made up the majority of participants in research on PrEP and…

Normative Guidance/Policies, Service Delivery

Document
9 March 2023

Making PrEP accessible: Updates on long-acting injectable options

Recording The objective of this webinar, presented by the International AIDS Society is to provide the latest updates on long-acting injectable PrEP, including science and research emerging from recent conferences. Participants will also hear the civil society perspective on the evolving PrEP landscape, as well as on-the-ground approaches to increase access to long-acting PrEP. Moderator:…

Community/Advocacy, Research

Event
17 February 2023

New PrEP Product Implementation Roadmap for PrEP vaginal ring and CAB for PrEP in Uganda

This presentation outlines the timelines for implementation of the dapivirine vaginal ring and cabotegravir (CAB) for PrEP in Uganda.

Research, Service Delivery

Document
10 February 2023

Coordinating Implementation Science for CAB for PrEP: Focus on Research and Surveillance during Pregnancy and Breastfeeding

These notes outline the key takeaways of a Think Tank focussing on CAB for PrEP implementation research and surveillance during pregnancy and breastfeeding. The Think Tank was part of an ongoing series by BioPIC and the WHO on coordinating implementation science for injectable CAB for PrEP.

Monitoring & Evaluation, Research

Document
7 February 2023

RISE CAB for PrEP Training Toolkit

With the release of the WHO Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention in 2022, HIV prevention programs and implementing partners are working to prepare for rapid expansion of additional methods of HIV pre-exposure prophylaxis (PrEP). Experience from the scale-up of previous HIV prevention programs demonstrates the advantages of ready-made provider capacity building resources…

Service Delivery

External Link
6 February 2023

Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men

This article from AIDS and Behavior describes the results of a discrete choice experiment on preferences for oral or injectable PrEP amongst gay, bisexual, and other men who have sex with men in the USA, including mode of administration, side-effects, monetary cost, and time cost.

Research

External Link
30 January 2023

An Update on Expanding HIV Preexposure Prophylaxis

This article from the Journal of the American Academy of Physicians Assistants describes how to better employ PrEP in the United States in light of changes to the Centers for Disease Control guidelines on PrEP counselling, monitoring, and delivery, and approval of injectable cabotegravir for PrEP by the US Food and Drug Administration.

Monitoring & Evaluation, Normative Guidance/Policies, Service Delivery

External Link
23 January 2023

Estimating the Impact of HIV PrEP Regimens Containing Long-acting Injectable Cabotegravir or Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine among Men who Have Sex with Men in the United States: A mathematical modelling study for HPTN 083

This article from The Lancet Regional Health- Americas describes the results of a modelling exercise which compares the potential population-level impact of oral PrEP (TDF/FTC) and Cabotegravir for PrEP among gay and bisexual men who have sex with men in Atlanta, Georgia, USA.

Research

External Link
17 January 2023

HIV Prevention Ambassador Training Package and Toolkit

The HIV Prevention Ambassador Training Package and Toolkit is designed for community-based organizations and other groups to train HIV Prevention Ambassadors with the goal of promoting the meaningful engagement of communities and potential and current PrEP users in the rollout of oral PrEP for HIV prevention.

Community/Advocacy, Demand Creation/Marketing

Document